Search - tctmd.com

Displaying 141 - 160 of 652

Sort: Relevancy | Date

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

News Conference News AHA 2022

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

Michael O'Riordan

November 06, 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

News Conference News AHA 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

Michael O'Riordan

November 06, 2022

CRISPR/Cas-9 Gene Editing Shows Promise in Transthyretin Amyloidosis

News Conference News AHA 2022

CRISPR/Cas-9 Gene Editing Shows Promise in Transthyretin Amyloidosis

Yael L. Maxwell

November 05, 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

News Conference News AHA 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

Michael O'Riordan

November 05, 2022

Too Few Veterans Get Intensified Lipid-Lowering Therapy After Coronary Events

News Daily News

Too Few Veterans Get Intensified Lipid-Lowering Therapy After Coronary Events

Yael L. Maxwell

October 24, 2022

PCSK9 Inhibitors Before PCI Swiftly Lower LDL-C in ACS Patients: EPIC-STEMI

News Conference News TCT 2022

PCSK9 Inhibitors Before PCI Swiftly Lower LDL-C in ACS Patients: EPIC-STEMI

September 22, 2022

Primordial Prevention Before End-stage CVD: Experts Call for a Fresh Focus

News Conference News TCT 2022

Primordial Prevention Before End-stage CVD: Experts Call for a Fresh Focus

Yael L. Maxwell

September 16, 2022

New on the Scene Nonstatin Drugs: Experts Provide Guidance

News Daily News

New on the Scene Nonstatin Drugs: Experts Provide Guidance

August 31, 2022

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

News Conference News ESC 2022

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

Michael O'Riordan

August 31, 2022

Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration

News Conference News ESC 2022

Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration

Michael O'Riordan

August 29, 2022

Polypill Bests Usual Care in Patients With Recent MI: SECURE

News Conference News ESC 2022

Polypill Bests Usual Care in Patients With Recent MI: SECURE

Michael O'Riordan

August 26, 2022

New USPSTF Statin Guidance: Familiar Advice, Some Holes to Fill

News Daily News

New USPSTF Statin Guidance: Familiar Advice, Some Holes to Fill

August 23, 2022

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

CASSISS: No Benefit of Stenting for Intracranial Stenosis

News Daily News

CASSISS: No Benefit of Stenting for Intracranial Stenosis

August 12, 2022

Intermittent Fasting Trial Comes Out (Partly) Positive, but CV Impact Mixed

News Daily News

Intermittent Fasting Trial Comes Out (Partly) Positive, but CV Impact Mixed

August 12, 2022

Genetic Study Hints at Cognitive Impact of Statins, but Experts Urge Caution

News Daily News

Genetic Study Hints at Cognitive Impact of Statins, but Experts Urge Caution

Michael O'Riordan

August 11, 2022

USPSTF Recommends Behavior Counseling to Improve Diet and Exercise Habits

News Daily News

USPSTF Recommends Behavior Counseling to Improve Diet and Exercise Habits

Michael O'Riordan

July 27, 2022

Ezetimibe Plus Moderate Statin a Welcome Alternative for High-Dose Monotherapy

News Daily News

Ezetimibe Plus Moderate Statin a Welcome Alternative for High-Dose Monotherapy

July 20, 2022

High Lp(a) May Predict Risk of CV and Limb Events in PAD

News Daily News

High Lp(a) May Predict Risk of CV and Limb Events in PAD

July 18, 2022

Desperate for Relief, Long COVID Patients Seek Apheresis, Other Untested Therapies

News Daily News

Desperate for Relief, Long COVID Patients Seek Apheresis, Other Untested Therapies

July 14, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.